NCT01597505View on ClinicalTrials.gov

Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)

PHASE3CompletedINTERVENTIONAL
Enrollment

606

Participants

Timeline

Start Date

May 16, 2012

Primary Completion Date

March 20, 2015

Study Completion Date

March 20, 2015

Conditions
Clostridium Difficile Infection
Interventions
DRUG

Surotomycin

250 mg Surotomycin over-encapsulated tablet administered orally, twice daily for a daily total dose of 500 mg, for 10 days

DRUG

Vancomycin

125 mg Vancomycin over-encapsulated capsule administered orally, four times daily for a daily total dose of 500 mg, for 10 days

DRUG

Placebo

Placebo for Surotomycin over-encapsulated tablet administered orally, twice daily for 10 days

All Listed Sponsors
lead

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT01597505 - Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005) | Biotech Hunter | Biotech Hunter